Core Viewpoint - Processa Pharmaceuticals, Inc. has announced a public offering of 28 million shares of common stock at a price of $0.25 per share, aiming to raise approximately $7 million for clinical trials and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes 28 million shares of common stock or pre-funded warrants, along with common warrants to purchase an additional 28 million shares at an exercise price of $0.25 per share [1]. - The offering is expected to close around June 18, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to continue the Phase 2 clinical trial for NCG-Cap, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing Next Generation Cancer (NGC) therapies that enhance safety and efficacy [5]. - The company's NGC drugs are modifications of existing FDA-approved oncology therapies, aiming to improve the metabolism and distribution of these drugs while retaining their cancer-killing mechanisms [5].

Core Viewpoint - Adial Pharmaceuticals, Inc. has announced a public offering of 11,100,000 shares of common stock and associated warrants, aiming to raise approximately $3.6 million for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes Series D warrants to purchase up to 11,100,000 shares and Series E warrants to purchase up to 8,325,000 shares, priced at a combined offering price of $0.3251 per share [1]. - The Series D and Series E warrants will have an exercise price of $0.35 per share, with Series D warrants expiring five years from stockholder approval and Series E warrants expiring eighteen months from stockholder approval [2]. - The closing of the offering is expected on or about June 18, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Existing Warrants Amendment - The company will amend existing Series B-1 and Series C-1 warrants to reduce their exercise price from $0.74 to $0.35 per share, subject to stockholder approval [4]. Group 4: Company Overview - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting Alcohol Use Disorder (AUD) [7]. - AD04 has shown promising results in a pivotal Phase 3 clinical trial, indicating potential for treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [7].

Core Viewpoint - Castellum, Inc. has successfully closed a public offering of 4,166,667 Units at a price of $1.20 per Unit, raising approximately $5.0 million in gross proceeds for working capital and general corporate purposes [1][2][3]. Group 1: Offering Details - The public offering consisted of Units, each comprising one share of common stock and one warrant to purchase one share of common stock [1]. - The warrants are immediately exercisable at a price of $1.22 per share and will expire 60 days from the date of issuance [1]. - The shares of common stock and warrants are immediately separable and were issued separately [1]. Group 2: Financial Information - Gross proceeds from the offering are approximately $5.0 million before deducting placement agent fees and offering expenses [2]. - The net proceeds will be utilized for working capital and general corporate purposes [2]. Group 3: Regulatory Information - A shelf registration statement on Form S-3 relating to the securities was previously filed with the U.S. Securities and Exchange Commission (SEC) [3]. - The offering was conducted under a preliminary prospectus supplement and an accompanying prospectus that have been filed with the SEC [4].

Core Viewpoint - Chanson International Holding has announced a public offering expected to generate approximately $8 million in gross proceeds to fund the expansion of its store network in China and the U.S. [1][3] Group 1: Offering Details - The offering consists of 16,000,000 units priced at $0.50 per unit, each unit includes one Class A ordinary share or a pre-funded warrant, along with Series A and Series B warrants [2] - Each Series A and Series B warrant has an exercise price of $0.525 per Class A ordinary share and can be exercised starting from the issuance date until two and a half years later [2] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to opening new stores in China and the U.S., with specific allocations depending on market conditions [3] Group 3: Company Overview - Chanson International Holding, founded in 2009, operates bakery, seasonal, and beverage products through its chain stores in China and the U.S., with 63 stores in China and 3 in New York City [5] - The company focuses on providing healthy, nutritious, and ready-to-eat food, utilizing advanced facilities and in-depth industry research to meet customer demand [5]

Core Points - Draganfly Inc. announced a public offering of 5,500,000 units at a price of US$2.50 per unit, aiming for gross proceeds of approximately US$13.75 million [1][3] - Each unit consists of one common share and one warrant, with the warrants having an exercise price of CA$5.0768 (or US$3.71) and expiring five years after issuance [1] - The net proceeds from the offering will be used for general corporate purposes, including funding new product capabilities, working capital, acquisitions, and research and development [3] Offering Details - The offering is expected to close on or about June 12, 2025, subject to customary closing conditions [3][4] - Maxim Group LLC is acting as the sole placement agent for the offering [2] - The offering is made under an effective shelf registration statement and a Canadian short form base shelf prospectus [5][6] Company Background - Draganfly Inc. is a pioneer in drone solutions, AI-driven software, and robotics, with over 25 years of innovation in the industry [8] - The company provides solutions for various sectors, including public safety, agriculture, industrial inspections, security, mapping, and surveying [8]

Core Viewpoint - Aduro Clean Technologies Inc. has announced a public offering of 947,868 common shares at a price of US$8.44 per share, aiming to raise approximately US$8 million for research and development, construction of a demonstration-scale plant, and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes 947,868 common shares and accompanying warrants to purchase 473,934 common shares, with each whole warrant exercisable at US$10.13 and expiring three years from issuance [1]. - The offering is managed by D. Boral Capital LLC as the sole book-running manager [2]. - An over-allotment option allows underwriters to purchase an additional 142,180 common shares and/or warrants for 71,090 common shares within 45 days [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to ongoing research and development costs, expenditures for the construction of a demonstration-scale plant, and any remaining funds for general corporate purposes and working capital [2]. Group 3: Regulatory Information - The offering is conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) and a Canadian short form base shelf prospectus [4]. - The base shelf prospectus has been filed with applicable securities commissions in Canada and the SEC, and is available for public access [5]. Group 4: Company Overview - Aduro Clean Technologies specializes in patented water-based technologies for recycling waste plastics, converting heavy crude into lighter oil, and transforming renewable oils into higher-value fuels or chemicals [7]. - The company's Hydrochemolytic™ Technology utilizes water as a key agent in a low-temperature chemistry platform, aiming to convert low-value feedstocks into valuable resources for the 21st century [7].

MIAMI BEACH, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) (“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced the launch of an underwritten public offering of 3,160,000 shares of its common stock. The underwriter will also have a 30-day option to purchase up to 474,000 additional shares of common stock. All of the shares of common stock in the offering are being sold by the Company. Vesey Street Capital Partners, L. ...

Core Viewpoint - Nuwellis, Inc. has announced a public offering of common stock and warrants to raise capital for working and corporate purposes, including potential acquisitions [1][2]. Group 1: Offering Details - The public offering includes 406,755 shares of common stock priced at $0.30 per share, along with pre-funded warrants for 14,085,998 shares priced at $0.2999 each [2]. - Accompanying the common stock are Series A Warrants for up to 43,478,259 shares and Series B Warrants for up to 14,492,753 shares, both with an exercise price of $0.30 [1][3]. - The offering is expected to close on or about June 10, 2025, subject to customary closing conditions [4]. Group 2: Warrant Details - Each pre-funded warrant has an exercise price of $0.0001 and is immediately exercisable until fully exercised [3]. - Series A and Series B Warrants will be exercisable for five years following stockholder approval, with Series A Warrants including a one-time reset of the exercise price under certain conditions [3]. - Series B Warrants offer a zero cash exercise option, allowing holders to receive shares without additional cash payment [3]. Group 3: Company Overview - Nuwellis, Inc. is a commercial-stage medical device company focused on treating fluid overload patients through innovative therapies [7]. - The company is commercializing the Aquadex SmartFlow system, which is designed for ultrafiltration therapy in patients unresponsive to medical management [8]. - Nuwellis is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [7].

Core Viewpoint - Helius Medical Technologies, Inc. has announced a public offering of 2,768,600 shares of Class A common stock and accompanying warrants, priced at $3.27 per share, aiming to raise approximately $9.1 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The public offering includes 2,768,600 shares of Class A common stock and warrants to purchase an equal number of shares at a combined price of $3.27 per share [1]. - Each warrant will expire in 2.5 years from issuance, is immediately exercisable at an initial price of $7.3575 per share, and can be exchanged for 2.0 common shares under a zero cash exercise option [2]. - The offering is expected to close on June 6, 2025, subject to customary closing conditions [3]. Group 2: Regulatory and Contact Information - A registration statement on Form S-1 was filed with the SEC and declared effective on June 4, 2025, with a final prospectus to be available on the SEC's website [4]. - Electronic copies of the prospectus can be obtained from Maxim Group LLC, the sole placement agent for the offering [4][7].

Group 1 - Orange County Bancorp, Inc. announced a public offering of 1,720,430 shares of common stock at a price of $23.25 per share, with an additional option for underwriters to purchase up to 258,064 shares [1][2] - The total gross proceeds from the offering are expected to be approximately $40.0 million, potentially increasing to $46.0 million if the underwriters fully exercise their option [2] - The net proceeds will be used for general corporate purposes, including investments in the Bank, enhancing regulatory capital and liquidity, and potential strategic acquisitions, although there are no current plans for specific acquisitions [2] Group 2 - The offering is expected to close on June 5, 2025, subject to customary closing conditions [2] - Piper Sandler & Co. and Stephens Inc. are acting as joint book-running managers for the offering [3] - Orange County Bancorp, Inc. is the parent company of Orange Bank & Trust Company, which has approximately $2.6 billion in total assets, and Hudson Valley Investment Advisors, Inc. [6]